As of November 6, 2026, Ani Pharmaceuticals Inc. is a publicly traded company (Nasdaq: ANIP); its largest reported holder is BlackRock, with 12.8% on Schedule 13G/A of July 27, 2026. The largest insider holding is Muthusamy Shanmugam, the chief operating officer and head of r, with 537,976 shares (2.2% of shares outstanding), per Form 4 of March 2, 2026 (Schedule 13G/A, July 27, 2026).
Is this your company?
About to sign with, pay or invest in Ani Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Ani Pharmaceuticals Inc. a real, registered company?
- Ani Pharmaceuticals Inc files with the SEC under CIK 1023024 (its SEC filings).
- Its shares are listed under the ticker ANIP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Princeton, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ANI PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Henry Gosebruch, Director (Form 8-K filed 2026-08-24). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-27).
Who are Ani Pharmaceuticals Inc.'s owners and officers?
Ani Pharmaceuticals Inc.: incorporated in Delaware; business address in Princeton, New Jersey; industry Pharmaceutical Preparations (Form D, 2026-08-24).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 12.8% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2025-11-13 | Millennium Management LLC | 0.3% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 11.3% |
| Schedule 13D/A, 2025-08-22 | Meridian Venture Partners Ii Gp, L.P. ("Gp") | 4.8% |
Questions about who owns Ani Pharmaceuticals Inc.
Who owns Ani Pharmaceuticals Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Ani Pharmaceuticals Inc.: Blackrock, Inc. (12.8%, Schedule 13G/A, filed 2026-07-27).
When did Blackrock, Inc. buy into Ani Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2025-10-17, reporting 11.3%; its latest, Schedule 13G/A filed 2026-07-27, reports 12.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Ani Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ani Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ani Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-24 | Henry Gosebruch | Director | appointed |
Which insiders own Ani Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief operating officer and head of r: 537,976 shares (2.2% of shares outstanding), 101,056 held directly and 436,920 indirectly (Form 4, 2026-03-02).
- , the chief executive and president: 333,689 shares (1.4% of shares outstanding) (Form 4, 2026-10-16).
- , the senior vice president - corp. dev. and strategy: 233,406 shares (0.96% of shares outstanding), 74,916 held directly and 158,490 indirectly (Form 4, 2026-03-02).
- , the chief financial officer and senior vice president: 166,143 shares (0.68% of shares outstanding) (Form 4, 2026-10-30).
- , the head of rare disease: 91,309 shares (0.37% of shares outstanding) (Form 4, 2026-03-13).
Shares outstanding: 24,422,240 as of 2013-02-28, from the company's latest SEC cover page.
How much has Ani Pharmaceuticals Inc. raised?
No fundraising or offering filing from Ani Pharmaceuticals Inc. is on file with us.
Keep reading
More on Ani Pharmaceuticals Inc. and the records around it.
Ani Pharmaceuticals Inc. elsewhere on the record
- Leadership changes Aug 2026
Companies that share a holder
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ani-pharmaceuticals